NYSE:NUVBPharmaceuticals
Assessing Nuvation Bio (NUVB) Valuation After The Eisai Taletrectinib Partnership Announcement
What the Eisai partnership means for Nuvation Bio
Nuvation Bio (NUVB) has drawn fresh attention after signing an exclusive license and collaboration agreement with Eisai covering taletrectinib for ROS1-positive non small cell lung cancer across multiple international markets.
Under the deal, Nuvation Bio is set to receive an upfront payment of €50 million, potential regulatory and commercial milestones of up to €145 million, and double digit tiered royalties on future net sales in Eisai’s...